T-Knife Therapeutics
Germany - BerlinBiotechnology
Focus: T-Knife Therapeutics is a Berlin-based public biotech company specializing in TCR (T-cell receptor) cell therapies for oncology, currently advancing autologous CD8+ T-cell therapies targeting solid tumors. The company operates as a clinical-stage player with one active Phase 1/2 program and emerging visibility in the European biotech landscape.
Profile data last refreshed 2h ago · AI intelligence enriched 3w ago
Funding Stage
PUBLIC
Open Jobs
0
About T-Knife Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow T-Knife Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from T-Knife Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Autologous CD8+ T-cells, transduced with MAGE-A1 directed TCR
Advanced Solid TumorsClinical Trials (1)
NCT05430555A Phase 1/ 2, First-in-Human, Open-Label, Accelerated-Titration, Two-Part Clinical Trial of TK-8001 in Patients With HLA-A*02:01 Genotype and Advanced-Stage/ Metastatic MAGE-A1+ Solid Tumors
Phase 1/2Help build intelligence for T-Knife Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.